Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship

McGill University

$67,500.00

Identifying the immune and stromal contributions underpinning skin toxicities from cancer immunotherapy.

FY 2024-25

Summary
Background and clinical challenge: A key objective of our translational research lab is to enhance cancer treatment by investigating the comprehensive effects of immune checkpoint inhibitors (ICIs). ICIs are designed to unlock the power of our immune system by blocking negative regulators of immune cell function. ICI are a revolutionary breakthrough in cancer therapy, and Health Canada is rapidly expanding their approved use, qualifying over 40% of cancers patients for these ICI therapies. However, with heightened immune activation, between 30-70% of these patients, depending on the therapy, will experience toxic side effects referred to as immune related adverse events (irAEs). The increased use of ICIs warrants priority research into irAEs. irAEs can lead to the discontinuation of potentially life-saving ICI treatment. Skin is the most frequently adversely affected organ, accounting for about 23% of all irAE subtypes and is often associated with itchiness, burning sensation, pain and visible rashes that significantly impact patient quality of life. Our limited understanding of skin irAEs leads to the use of treatments used in non-ICI induced skin diseases, primarily involving immunosuppressive agents and small molecule biologic drugs. This not only leads to poor management of skin irAEs but may also counteract the immune-activating action of ICIs, thus risking an increase in cancer progression. Therefore, this proposal is aligned with the CRS-CIHR ‘Cancer Survivorship Research’ vision, which seeks to improve health outcomes for patients by funding research to prevent or lessen adverse side effects from cancer therapies. Objective and hypothesis: Our long-term objective is to identify biomarkers that can be used to inform treatments to better manage skin irAEs and thus optimize the anti-cancer benefits of ICIs. We hypothesize that skin irAEs are characterized by the presence of T cells with a mixed Th1 and Th17 phenotype that cross-talk with skin fibroblasts to orchestrate a feed-forward paracrine signaling loop to exacerbate inflammation. This hypothesis will be tested by generating high quality large-scale spatial profiling data characterizing the tissue microenvironment of skin irAE biopsies and matched control skin samples. To test potential therapies to manage skin irAE without dampening the anti-tumor benefit of ICI, we developed and will use a pre-clinical mouse model which couples the onset of skin irAE and melanoma, a tumor type commonly associated with skin irAEs. Specific Aims and Methodology: AIM 1: Define circulating and tissue microenvironment signatures that differentiate skin irAEs from non-ICI related skin toxicities. We will use the SomaScan platform to identify a cytokine/chemokine signature in the blood of patients who will receive ICI that will serve as biomarkers for identifying those at risk of developing skin irAEs. We will also use our highly multiplexed immunostaining antibody panel (including antibodies to detect immune cell subtypes, skin specific cells, and fibroblasts) for use in the PhenoCycler platform, which will identify the skin resident cell-cell interactions that underpin the skin irAEs. irAE skin biopsies are continually banked from patients enrolled in the Montreal Immune Related Adverse Events (MIRAE) Biobank. The imaging on irAE patient skin samples will be compared against autoimmune skin diseases (psoriasis and dermatitis) and skin from healthy volunteers. We expect to uncover druggable features of the skin irAEs that are crucial for managing the irAE while ensuring positive ICI outcomes. AIM 2: Use a novel pre-clinical mouse model of skin irAEs to test novel therapies. We have established a skin irAE mouse model that mimics the immunologic signatures reported in human studies where skin irAEs have been investigated.
Program
CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
537935
Name
Del Rincon Sonia V
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Identifying the immune and stromal contributions underpinning skin toxicities from cancer immunotherapy.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
CIHR-ICR / Cancer Research Society Partnership - Res. Grants-Survivorship
Keyworddelim
Cancer
Abstract
Background and clinical challenge: A key objective of our translational research lab is to enhance cancer treatment by investigating the comprehensive effects of immune checkpoint inhibitors (ICIs). ICIs are designed to unlock the power of our immune system by blocking negative regulators of immune cell function. ICI are a revolutionary breakthrough in cancer therapy, and Health Canada is rapidly expanding their approved use, qualifying over 40% of cancers patients for these ICI therapies. However, with heightened immune activation, between 30-70% of these patients, depending on the therapy, will experience toxic side effects referred to as immune related adverse events (irAEs). The increased use of ICIs warrants priority research into irAEs. irAEs can lead to the discontinuation of potentially life-saving ICI treatment. Skin is the most frequently adversely affected organ, accounting for about 23% of all irAE subtypes and is often associated with itchiness, burning sensation, pain and visible rashes that significantly impact patient quality of life. Our limited understanding of skin irAEs leads to the use of treatments used in non-ICI induced skin diseases, primarily involving immunosuppressive agents and small molecule biologic drugs. This not only leads to poor management of skin irAEs but may also counteract the immune-activating action of ICIs, thus risking an increase in cancer progression. Therefore, this proposal is aligned with the CRS-CIHR ‘Cancer Survivorship Research’ vision, which seeks to improve health outcomes for patients by funding research to prevent or lessen adverse side effects from cancer therapies. Objective and hypothesis: Our long-term objective is to identify biomarkers that can be used to inform treatments to better manage skin irAEs and thus optimize the anti-cancer benefits of ICIs. We hypothesize that skin irAEs are characterized by the presence of T cells with a mixed Th1 and Th17 phenotype that cross-talk with skin fibroblasts to orchestrate a feed-forward paracrine signaling loop to exacerbate inflammation. This hypothesis will be tested by generating high quality large-scale spatial profiling data characterizing the tissue microenvironment of skin irAE biopsies and matched control skin samples. To test potential therapies to manage skin irAE without dampening the anti-tumor benefit of ICI, we developed and will use a pre-clinical mouse model which couples the onset of skin irAE and melanoma, a tumor type commonly associated with skin irAEs. Specific Aims and Methodology: AIM 1: Define circulating and tissue microenvironment signatures that differentiate skin irAEs from non-ICI related skin toxicities. We will use the SomaScan platform to identify a cytokine/chemokine signature in the blood of patients who will receive ICI that will serve as biomarkers for identifying those at risk of developing skin irAEs. We will also use our highly multiplexed immunostaining antibody panel (including antibodies to detect immune cell subtypes, skin specific cells, and fibroblasts) for use in the PhenoCycler platform, which will identify the skin resident cell-cell interactions that underpin the skin irAEs. irAE skin biopsies are continually banked from patients enrolled in the Montreal Immune Related Adverse Events (MIRAE) Biobank. The imaging on irAE patient skin samples will be compared against autoimmune skin diseases (psoriasis and dermatitis) and skin from healthy volunteers. We expect to uncover druggable features of the skin irAEs that are crucial for managing the irAE while ensuring positive ICI outcomes. AIM 2: Use a novel pre-clinical mouse model of skin irAEs to test novel therapies. We have established a skin irAE mouse model that mimics the immunologic signatures reported in human studies where skin irAEs have been investigated.
Competitiondate
202502
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Del Rincon, Sonia V
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $67,500~ $0~